American Tech Today
SEE OTHER BRANDS

Hottest science and technology news from the United States

American Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.

Press releases published on May 12, 2025

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg …

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results

Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026 …

Hudbay Delivers Strong First Quarter 2025 Results Driven by Gold Production and Record Cost Performance

Hudbay Delivers Strong First Quarter 2025 Results Driven by Gold Production and Record Cost Performance

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) today released its first quarter 2025 financial results. All amounts are in U.S. dollars, unless otherwise noted. "Our strong results in the first …

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma

Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated the potential for durable disease …

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

New litigation filed against Liquidia in U.S. District Court for the Middle District of North Carolina alleges infringement of UTHR’s ‘782 patent and seeks to enjoin Liquidia from commercializing YUTREPIA ‘782 patent claims same general subject matter as …

GFG Discovers New Gold Zone in Footwall and Extends Mineralization to Near-Surface at Aljo Gold Project, Timmins, ON

GFG Discovers New Gold Zone in Footwall and Extends Mineralization to Near-Surface at Aljo Gold Project, Timmins, ON

KEY HIGHLIGHTS: ALJ-24-019 intersected multiple high-grade intervals relating to the Hangingwall (“HW”), Main and newly expanded Footwall (“FW”) Zones. HW Zone returned 4.39 grams of gold per tonne (“g/t Au”) over 3.4 metres (“m”), 7.76 g/t Au over 1.5 m …

Alation Launches Data Products Builder Agent to Power AI-Ready Data

Alation Launches Data Products Builder Agent to Power AI-Ready Data

LONDON, May 12, 2025 (GLOBE NEWSWIRE) -- Alation Inc., the data intelligence company, today announced the launch of its Data Products Builder Agent, an AI-powered tool that helps data teams turn messy, raw data into trusted, reusable data products. It …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service